Quick Answer
Crinetics Pharmaceuticals, Inc. reported Total Revenue of $7.70 million for fiscal year 2025.
Crinetics Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $7.70M +640.7% |
$1.04M -74.1% |
$4.01M -15.3% |
$4.74M +339.4% |
$1.08M +1418.3% |
$71.0K -94.0% |
| Revenue (ASC 606) | $7.70M +640.7% |
$1.04M -74.1% |
$4.01M | $0.00 | $0.00 -100.0% |
$71.0K -94.0% |
| Net Income | -$465.32M -55.9% |
-$298.41M -39.1% |
-$214.53M -30.9% |
-$163.92M -52.3% |
-$107.64M -45.8% |
-$73.81M -46.4% |
| Diluted EPS | -$4.95 -34.1% |
-$3.69 +0.0% |
-$3.69 -17.1% |
-$3.15 -12.5% |
-$2.80 -15.7% |
-$2.42 |
| Total Assets | $1.13B -21.5% |
$1.43B +125.8% |
$635.35M +80.4% |
$352.18M +0.3% |
$351.01M +91.3% |
$183.44M +40.7% |
| Cash and Equivalents | $101.54M -61.6% |
$264.55M +381.9% |
$54.90M +68.0% |
$32.67M -83.7% |
$200.69M +115.6% |
$93.09M +130.8% |
| Stockholders Equity | $992.08M -25.1% |
$1.32B +145.7% |
$539.11M +70.4% |
$316.33M -4.7% |
$331.94M +96.5% |
$168.92M +44.2% |
| R&D Expense | $332.06M +38.3% |
$240.16M +42.5% |
$168.53M +29.4% |
$130.22M +54.6% |
$84.25M +47.8% |
$57.00M +37.3% |
| Operating Income | -$516.77M -52.5% |
-$338.85M -52.2% |
-$222.61M -32.6% |
-$167.88M -55.9% |
-$107.70M -43.7% |
-$74.95M -39.2% |
| Shares Outstanding | 95.58M +2.9% |
92.93M +187.3% |
32.34M -40.0% |
53.88M +13.2% |
47.60M +44.2% |
33.00M +36.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $143.0K | — | -86.1% |
| Revenue (ASC 606) | September 30, 2025 | $143.0K | — | -86.1% |
| Net Income | September 30, 2025 | -$130.09M | -69.3% | -12.5% |
| Diluted EPS | September 30, 2025 | -$1.38 | -43.7% | -12.2% |
| Total Assets | September 30, 2025 | $1.20B | +27.6% | -7.3% |
| Cash and Equivalents | September 30, 2025 | $110.90M | -65.0% | +106.4% |
| Stockholders Equity | September 30, 2025 | $1.07B | +28.7% | -8.5% |
| R&D Expense | September 30, 2025 | $90.46M | +46.1% | +12.7% |
| Operating Income | September 30, 2025 | -$142.59M | -62.4% | -10.4% |
| Shares Outstanding | September 30, 2025 | 94.55M | +17.0% | +0.4% |
- Crinetics Pharmaceuticals, Inc. reported Total Revenue of $7.70 million for fiscal year 2025.
- Crinetics Pharmaceuticals, Inc. showed an increase of +640.7% in Total Revenue compared to the prior fiscal year.
- Crinetics Pharmaceuticals, Inc. reported Revenue (ASC 606) of $7.70 million for fiscal year 2025.
- Crinetics Pharmaceuticals, Inc. showed an increase of +640.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Crinetics Pharmaceuticals, Inc. reported Net Income of -$465.32 million for fiscal year 2025.
- Crinetics Pharmaceuticals, Inc. showed a decrease of -55.9% in Net Income compared to the prior fiscal year.
- Crinetics Pharmaceuticals, Inc. reported Diluted EPS of $4.95 per share (loss) for fiscal year 2025.
- Crinetics Pharmaceuticals, Inc. showed a decrease of -34.1% in Diluted EPS compared to the prior fiscal year.
- Crinetics Pharmaceuticals, Inc. reported Total Assets of $1.13 billion for fiscal year 2025.
- Crinetics Pharmaceuticals, Inc. showed a decrease of -21.5% in Total Assets compared to the prior fiscal year.
- Crinetics Pharmaceuticals, Inc. reported Cash and Equivalents of $101.54 million for fiscal year 2025.
- Crinetics Pharmaceuticals, Inc. showed a decrease of -61.6% in Cash and Equivalents compared to the prior fiscal year.
- Crinetics Pharmaceuticals, Inc. reported Stockholders Equity of $992.08 million for fiscal year 2025.
- Crinetics Pharmaceuticals, Inc. showed a decrease of -25.1% in Stockholders Equity compared to the prior fiscal year.
- Crinetics Pharmaceuticals, Inc. reported R&D Expense of $332.06 million for fiscal year 2025.
- Crinetics Pharmaceuticals, Inc. showed an increase of +38.3% in R&D Expense compared to the prior fiscal year.
- Crinetics Pharmaceuticals, Inc. reported Operating Income of -$516.77 million for fiscal year 2025.
- Crinetics Pharmaceuticals, Inc. showed a decrease of -52.5% in Operating Income compared to the prior fiscal year.
- Crinetics Pharmaceuticals, Inc. reported Shares Outstanding of 95.58 million shares for fiscal year 2025.
- Crinetics Pharmaceuticals, Inc. showed an increase of +2.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: